Literature DB >> 8456934

Two distinct pathological syndromes in male CBA/J inbred mice with chronic Schistosoma mansoni infections.

G S Henderson1, N A Nix, M A Montesano, D Gold, G L Freeman, T L McCurley, D G Colley.   

Abstract

Humans chronically infected with Schistosoma mansoni most commonly present with the relatively asymptomatic intestinal form of the disease, whereas a small minority develop hepatosplenism characterized by severe hepatic disease with portal hypertension. Investigation of hypotheses describing the pathogenic mechanisms underlying the clinical forms of the human disease has been limited by the absence of an animal model that predictably develops such a spectrum of disease. We report that inbred male CBA/J mice that are chronically infected with S. mansoni develop two distinct syndromes, hypersplenomegaly syndrome (HSS) and moderate splenomegaly syndrome (MSS). Pathologically and immunologically, MSS and HSS remarkably parallel the intestinal and hepatosplenic clinical forms, respectively, in humans. HSS affects approximately 20% of these mice and consists of massive splenomegaly, ascites, thymic atrophy, severe anemia, and cachexia. The remaining majority of mice with MSS develop moderate splenomegaly only. Histopathological features of HSS include 1) relatively extensive hepatic fibrosis and granulomatous inflammation, 2) splenic congestion, 3) lymph node plasmacytosis, and 4) worms and eggs in the pulmonary vasculature. Immunologically, the idiotypes present on antisoluble egg antigen antibodies from HSS mice are distinct from those from mice with acute infections or the chronic MSS infection. These idiotypic differences are similar to those observed in patients with intestinal and hepatosplenic forms of the disease and may have regulatory importance. Investigation of the cellular and molecular events that lead to the development of MSS and HSS may advance current understanding of the pathogenesis of the clinical forms of chronic schistosomiasis in humans.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8456934      PMCID: PMC1886796     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  43 in total

1.  The etiology of hepato-splenic Schistosomiasis mansoni in mice.

Authors:  K S WARREN
Journal:  Am J Trop Med Hyg       Date:  1961-11       Impact factor: 2.345

2.  Recombinant IL-2 therapy reverses diminished granulomatous responsiveness in anti-L3T4-treated, Schistosoma mansoni-infected mice.

Authors:  R C Mathew; S Ragheb; D L Boros
Journal:  J Immunol       Date:  1990-06-01       Impact factor: 5.422

3.  A quantitative post-mortem study of Schistosomiasis mansoni in man.

Authors:  A W Cheever
Journal:  Am J Trop Med Hyg       Date:  1968-01       Impact factor: 2.345

4.  Variation of hepatic fibrosis and granuloma size among mouse strains infected with Schistosoma mansoni.

Authors:  A W Cheever; R H Duvall; T A Hallack; R G Minker; J D Malley; K G Malley
Journal:  Am J Trop Med Hyg       Date:  1987-07       Impact factor: 2.345

5.  Immune responses during human Schistosoma mansoni. XVII. Recognition by monoclonal anti-idiotypic antibodies of several idiotopes on a monoclonal anti-soluble schistosomal egg antigen antibody and anti-soluble schistosomal egg antigen antibodies from patients with different clinical forms of infection.

Authors:  M A Montesano; G L Freeman; G Gazzinelli; D G Colley
Journal:  J Immunol       Date:  1990-11-01       Impact factor: 5.422

6.  Anti-idiotypic T lymphocyte responsiveness in murine Schistosomiasis mansoni.

Authors:  M R Powell; D G Colley
Journal:  Cell Immunol       Date:  1987-02       Impact factor: 4.868

7.  Pathogenesis of pipe-stem fibrosis of the liver (experimental observation on murine schistosomiasis).

Authors:  Z A Andrade
Journal:  Mem Inst Oswaldo Cruz       Date:  1987 Jul-Sep       Impact factor: 2.743

8.  Differential immunoregulation of granulomatous inflammation, portal hypertension, and hepatic fibrosis in murine schistosomiasis mansoni.

Authors:  G R Olds; S el Meneza; A F Mahmoud; T F Kresina
Journal:  J Immunol       Date:  1989-05-15       Impact factor: 5.422

9.  H-2 linked immune response to murine experimental Schistosoma mansoni infections.

Authors:  F H Claas; A M Deelder
Journal:  J Immunogenet       Date:  1979-06

10.  Demonstration of splenic auto-anti-idiotypic plaque-forming cells in mice infected with Schistosoma mansoni.

Authors:  M R Powell; D G Colley
Journal:  J Immunol       Date:  1985-06       Impact factor: 5.422

View more
  14 in total

Review 1.  Murine schistosomiasis as a model for human schistosomiasis mansoni: similarities and discrepancies.

Authors:  Rashad A Abdul-Ghani; Azza A Hassan
Journal:  Parasitol Res       Date:  2010-04-06       Impact factor: 2.289

2.  Identification of cytokeratin 18 as a biomarker of mouse and human hepatosplenic schistosomiasis.

Authors:  Bhagyashree Manivannan; Pisana Rawson; T William Jordan; Diana M S Karanja; Pauline N M Mwinzi; William Evan Secor; Anne Camille La Flamme
Journal:  Infect Immun       Date:  2011-02-28       Impact factor: 3.441

3.  Differential Vbeta T-cell receptor usage during chronic experimental schistosomiasis corresponds with distinct pathological presentations.

Authors:  W E Secor; G L Freeman
Journal:  Infect Immun       Date:  2001-06       Impact factor: 3.441

4.  Silymarin treatment reduces granuloma and hepatic fibrosis in experimental schistosomiasis.

Authors:  Hílton Antonio Mata-Santos; Fabiana Gonçalves Lino; Carolina Carneiro Rocha; Claudia Neto Paiva; Morgana Teixeira Lima Castelo Branco; Alexandre dos Santos Pyrrho
Journal:  Parasitol Res       Date:  2010-08-07       Impact factor: 2.289

5.  Schistosoma mansoni soluble egg antigens trigger erythrocyte cell death.

Authors:  Ravi S Kasinathan; Robert M Greenberg
Journal:  Cell Physiol Biochem       Date:  2010-10-29

6.  Serum osteopontin is a biomarker of severe fibrosis and portal hypertension in human and murine schistosomiasis mansoni.

Authors:  Thiago Almeida Pereira; Wing-Kin Syn; Fausto E L Pereira; José Roberto Lambertucci; William Evan Secor; Anna Mae Diehl
Journal:  Int J Parasitol       Date:  2016-10-10       Impact factor: 3.981

7.  Differential patterns of liver proteins in experimental murine hepatosplenic schistosomiasis.

Authors:  B Manivannan; P Rawson; T W Jordan; W E Secor; A C La Flamme
Journal:  Infect Immun       Date:  2009-11-23       Impact factor: 3.441

8.  Dexamethasone treatment improves morphological and hematological parameters in chronic experimental schistosomiasis.

Authors:  Alexandre S Pyrrho; Henrique Leonel Lenzi; Juliene Antonio Ramos; Roberto Moura-Neto; Fabio Christiane O F Cachem; Célia Santos da Silva; Christina Maeda Takiya; Cerli Rocha Gattass
Journal:  Parasitol Res       Date:  2004-03-04       Impact factor: 2.289

9.  Idiotypes expressed early in experimental Schistosoma mansoni infections predict clinical outcomes of chronic disease.

Authors:  M Angela Montesano; Daniel G Colley; Margaret T Willard; George L Freeman; W Evan Secor
Journal:  J Exp Med       Date:  2002-05-06       Impact factor: 14.307

10.  Neonatal idiotypic exposure alters subsequent cytokine, pathology, and survival patterns in experimental Schistosoma mansoni infections.

Authors:  M A Montesano; D G Colley; S Eloi-Santos; G L Freeman; W E Secor
Journal:  J Exp Med       Date:  1999-02-15       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.